HRS 9821
Alternative Names: HRS-9821Latest Information Update: 05 Jul 2024
At a glance
- Originator Guangdong Hengrui Pharmaceutical
- Class Bronchodilators
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 05 Jul 2024 Jiangsu Hengrui Pharmaceuticals pipeline, July 2024- MoA added, thes reqst sent
- 12 Jan 2023 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation) (NCT05622864)
- 21 Nov 2022 Guangdong Hengrui Pharmaceutical plans a phase-I trial for Chronic obstructive pulmonary disease in China (NCT05622864; HRS-9821-I-101)